Amelia Seifalian on Muck Rack

Amelia Seifalian

London
As seen in: MDPI, The Lancet
Director/Professor Nanotechnology & Regenerative Medicine, NanoRegMed Ltd, (a.seifalian@gmail.com)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Amelia

Contact Amelia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Novel Graphene-Based Nanomaterial for the Development of a Pelvic Implant to Treat Pelvic Organ Prolapse

|
By Amelia Seifalian, Alex Digesu, Vik Khullar
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared View Duplicates (185) Issue with article?

Polypropylene Pelvic Mesh: What Went Wrong and What Will Be of the Future?

|
By Amelia Seifalian, Alex Digesu, Zeinab Basma, Vikram Khullar
| MDPI
1. Introduction The use of transvaginal pelvic mesh for prolapse surgery has become a highly controversial and widely discussed topic among gynaecologists in recent years. When polypropylene (PP) pelvic mesh was first introduced to the healthcare market, it was described to be a simple and permanent tool for treating pelvic organ prolapses (POP).
Open in Who Shared Issue with article?

Dysmenorrhoea: Can Medicinal Cannabis Bring New Hope for a Collective Group of Women Suffering in Pain, Globally?

|
By Amelia Seifalian, Julian Kenyon, Vik Khullar
| MDPI
Abstract : Dysmenorrhoea effects up to 90% of women of reproductive age, with medical management options including over-the-counter analgesia or hormonal contraception. There has been a recent surge in medicinal cannabis research and its analgesic properties. This paper aims to critically investigate the current research of medicinal cannabis for pain relief and to discuss its potential application to treat dysmenorrhoea.
Open in Who Shared Issue with article?
See all 5 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified